Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of a myocardial infarction symptoms. Clinical selection for Reteplase should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
10U bolus dose followed by a second 10U bolus dose 30 minutes later (double bolus). Each bolus is administered as a slow intravenous injection within 2 minutes. Heparin and acetylsalicylic acid should be administered before and following its administration to reduce the risk of re-thrombosis.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.